Background: Maternal Diabetes and Fetal Neurodevelopment
Maternal diabetes represents one of the most prevalent metabolic complications affecting pregnancy worldwide, with gestational diabetes mellitus (GDM) occurring in approximately 10-15% of pregnancies and pregestational diabetes in 1-2%. Beyond the well-established risks of macrosomia, birth complications, and neonatal hypoglycemia, emerging evidence suggests that maternal hyperglycemia may exert lasting effects on the developing fetal brain.
The biological plausibility for impaired neurodevelopment stems from multiple mechanisms. Maternal hyperglycemia creates a hyperinsulinemic fetal environment, diverting glucose and nutrients away from optimal brain development. Additionally, oxidative stress, inflammatory cascades, and epigenetic modifications triggered by maternal diabetes may alter normal neural migration, synaptogenesis, and myelination during critical windows of brain development. These processes are particularly active during the third trimester and early postnatal period, coinciding with the timing of the developmental assessments examined in this study.
Despite growing recognition of associations between maternal diabetes and neurodevelopmental disorders such as autism spectrum disorder and attention-deficit/hyperactivity disorder, the specific impact on early milestone attainment across developmental domains remains incompletely characterized. This knowledge gap limits the ability of clinicians to provide targeted surveillance and early intervention for at-risk infants.
Study Design and Population
Researchers conducted a nationwide retrospective cohort study utilizing linked data from national maternal-child health clinics and hospital discharge registries. The study population comprised 466,462 term singleton infants born between January 2018 and December 2021, providing a robust sample representative of routine clinical practice.
Developmental outcomes were assessed through nurse-administered structured assessments performed at routine well-child visits extending through 24 months of age. These standardized evaluations captured milestone attainment across five developmental domains: language, personal-social, gross motor, fine motor, and adaptive skills. The primary exposure variables included maternal GDM, pregestational type 1 diabetes, and pregestational type 2 diabetes, with offspring of mothers without diabetes serving as the control group.
The study estimated adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) for failure to attain developmental milestones, stratifying analyses by diabetes type and infant sex to identify differential risk patterns.
Key Findings: Diabetes Type Matters for Neurodevelopmental Risk
The most striking finding was the clear gradient of risk according to diabetes type. Pregestational diabetes was associated with significantly increased risk for delayed milestone attainment across multiple developmental domains, with the magnitude of risk varying substantially by diabetes classification.
Type 1 Diabetes: Highest Risk, Female-Driven
Offspring of mothers with type 1 diabetes demonstrated the highest overall risk for developmental delays, showing elevated hazard ratios in language (aHR, 1.44; 95% CI, 1.09-1.89), personal-social (aHR, 1.64; 95% CI, 1.14-2.36), and gross motor (aHR, 1.41; 95% CI, 1.05-1.89) domains. Notably, the association between type 1 diabetes and developmental delay was predominantly driven by female offspring, suggesting sex-specific vulnerability to maternal metabolic disturbances during fetal brain development.
Type 2 Diabetes: Elevated but Moderate Risk
Infants exposed to maternal type 2 diabetes also showed increased risks for delayed milestones, though generally lower than those observed with type 1 diabetes. This finding suggests that the duration and timing of diabetes exposure, which typically differs between type 1 and type 2 diabetes, may influence neurodevelopmental outcomes.
Gestational Diabetes: Limited Domain-Specific Effects
In contrast to pregestational diabetes, GDM was associated with only a modestly increased risk for delayed milestone attainment, and notably, this risk was limited to the fine motor domain (aHR, 1.11; 95% CI, 1.06-1.16). This domain-specific, attenuated association suggests that the metabolic milieu of GDM, which typically emerges later in pregnancy, may have more selective effects on neurodevelopment compared to chronic hyperglycemia present from conception.
Expert Commentary: Interpreting the Differential Risk Profile
The differential risk pattern observed across diabetes types carries important implications for understanding the biological mechanisms underlying maternal diabetes effects on the fetal brain. The gradient of risk—from type 1 diabetes (highest) to type 2 diabetes (moderate) to GDM (modest, domain-specific)—suggests that both the timing and duration of hyperglycemic exposure influence neurodevelopmental vulnerability.
The predominance of female offspring in driving the type 1 diabetes-associated delays raises intriguing questions about sex-specific biological susceptibility. Potential explanations include differential placental responses to hyperglycemic stress, sex-chromosome-linked gene expression patterns affecting neural development, or hormonal interactions between maternal and fetal metabolic systems. These findings warrant further investigation in mechanistic studies specifically designed to examine sex differences.
The clinical significance extends beyond statistical significance: hazard ratios exceeding 1.4-1.6 for specific domains translate to clinically meaningful delays that may affect school readiness, social functioning, and long-term developmental trajectories. The fine motor domain spared in pregestational diabetes exposure, yet selectively affected by GDM, suggests that certain neural circuits may be particularly vulnerable during specific developmental windows.
Strengths and Limitations
Major strengths of this study include its large, population-based sample providing substantial statistical power, the use of standardized nurse-administered developmental assessments, and the comprehensive linked data enabling adjustment for potential confounders. The stratification by both diabetes type and infant sex allows for nuanced risk characterization.
Limitations include the retrospective design precluding causal inference, potential residual confounding despite statistical adjustment, and the focus on term infants which may not generalize to preterm populations who face even higher neurodevelopmental risks. Additionally, the study assessed milestone attainment only through 24 months; whether these delays persist, resolve, or portend later neurodevelopmental disorders requires longitudinal follow-up.
Clinical Implications and Future Directions
These findings support the rationale for enhanced developmental surveillance of infants born to mothers with pregestational diabetes, with particular attention to female offspring who appear most vulnerable. Clinicians should consider earlier and more frequent developmental screening for these at-risk populations, with low thresholds for referral to early intervention services when delays are identified.
Future research should focus on unraveling the biological mechanisms underlying these sex-specific vulnerabilities, evaluating the long-term trajectories of affected children into preschool and school age, and ultimately developing targeted preventive strategies. Studies examining the potential benefit of optimized glycemic control before conception and throughout pregnancy in reducing neurodevelopmental risk would be particularly valuable.
Conclusion
This landmark study demonstrates that maternal diabetes type significantly shapes the neurodevelopmental landscape of exposed offspring. The clear risk gradient—from type 1 diabetes conferring the highest burden, through type 2 diabetes, to the more modest and domain-specific effects of GDM—provides clinicians with nuanced risk stratification tools. The identification of female offspring as particularly vulnerable to type 1 diabetes-associated delays opens new avenues for sex-specific investigation in developmental programming. As the global burden of diabetes in pregnancy continues to rise, understanding these early neurodevelopmental consequences becomes increasingly critical for optimizing outcomes for the next generation.
References
1. Kerem L, Guedalia J, Lipschuetz M, Sehtman-Shachar DR, Cahen-Peretz A, Cohen SM, Novoselsky-Persky M, Amsalem H, Shefer G, Drawshy S, Calderon-Margalit R, Beharier O. Maternal Diabetes and Early Neurodevelopment: Differential Milestone Attainment in Offspring by Diabetes Type. Diabetes Care. 2026-Apr-01;49(4):641-649. PMID: 41678362.
